Abrdn Life Sciences Investors (HQL)

HQL Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Cash & Equivalents	0.08	0	0	0	-
Cash & Short-Term Investments	0.08	0	0	0	-
Cash Growth	7553700.00%	-99.78%	-55.05%	-	-
Accounts Receivable	1.14	0.23	0.62	0.15	0.17
Other Receivables	0.01	0.01	-	-	-
Receivables	1.15	0.24	0.62	0.15	0.17
Prepaid Expenses	0.04	0.04	0.03	0.03	0.03
Other Current Assets	-	-	11.09	8.47	4.97
Total Current Assets	1.26	0.28	11.74	8.64	5.16
Long-Term Investments	465.24	446.4	391.52	481.17	419.36
Other Long-Term Assets	48.88	13.9	11.47	44.37	59.64
Total Assets	515.38	460.58	414.73	534.19	484.17
Accounts Payable	0.72	0	5.1	-	-
Accrued Expenses	0.57	0.84	0.63	0.7	0.57
Short-Term Debt	-	-	11.09	10.04	0.01
Other Current Liabilities	0.43	0.05	-	-	-
Total Current Liabilities	1.73	0.89	16.82	10.75	0.58
Other Long-Term Liabilities	-	-	-	-	0.01
Total Liabilities	1.73	0.89	16.82	10.75	0.6
Common Stock	0.3	0.28	0.26	0.25	0.24
Additional Paid-In Capital	435.76	415.29	388.1	372.49	356.3
Retained Earnings	77.6	44.13	9.55	150.7	127.03
Shareholders' Equity	513.66	459.69	397.9	523.44	483.57
Total Liabilities & Equity	515.38	460.58	414.73	534.19	484.17
Total Debt	-	-	11.09	10.04	0.01
Net Cash (Debt)	0.08	0	-11.09	-10.04	-0.01
Net Cash Growth	7553700.00%	-	-	-	-
Net Cash Per Share	0.00	-	-0.43	-0.41	-0.00
Filing Date Shares Outstanding	29.6	28.06	25.68	24.67	23.88
Total Common Shares Outstanding	29.6	28.06	25.68	24.67	23.88
Working Capital	-0.46	-0.61	-5.08	-2.1	4.58
Book Value Per Share	17.35	16.38	15.49	21.22	20.25
Tangible Book Value	513.66	459.69	397.9	523.44	483.57
Tangible Book Value Per Share	17.35	16.38	15.49	21.22	20.25

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q